Immunotherapy Strategies for Pancreatic Cancer
Summary
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, owing to its dense desmoplastic stroma, profound immunosuppression and late clinical presentation. Immunotherapy seeks to overcome these barriers by harnessing or redirecting the patient’s immune system to recognise and eliminate tumour cells. Strategies include immune checkpoint blockade to reinvigorate exhausted T lymphocytes, cancer vaccines designed to prime antigen-specific immunity, adoptive cell therapies such as chimeric antigen receptor T cells, and oncolytic viruses that provoke local inflammation and antigen release. Central to all approaches is modulation of the tumour microenvironment (TME), which is rich in immunosuppressive cells—myeloid-derived suppressor cells, tumour-associated macrophages and regulatory T cells—and stroma that impedes lymphocyte infiltration. Combination regimens pairing immunotherapy with chemotherapy, radiotherapy or targeted agents aim to debulk stroma, enhance antigen presentation and convert ‘cold’ tumours into inflamed ones. Advances in neoantigen discovery and delivery platforms have enabled personalised vaccination and adoptive transfer, while novel agents target stromal pathways to normalise vasculature and facilitate immune cell trafficking. Despite limited single-agent activity to date, emerging data support strategic combinations and biomarker-driven patient selection as the path to clinical benefit in this challenging disease.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Immunotherapy Strategies for Pancreatic Cancer publication trend
The graph below shows the total number of articles in immunotherapy strategies for pancreatic cancer across all publications each year (not limited to Nature Index journals).
Technical terms
Pancreatic ductal adenocarcinoma (PDAC): The most common form of pancreatic cancer, characterised by glandular differentiation within the pancreatic ducts.
Tumour microenvironment (TME): The cellular and acellular milieu surrounding a tumour, including immune cells, stromal cells and extracellular matrix.
Immune checkpoint inhibitors: Agents that block regulatory receptors such as PD-1 or CTLA-4, restoring T-cell activity against tumour antigens.
Cancer vaccines: Therapeutic preparations of tumour antigens, peptides or nucleic acids intended to elicit antigen-specific immune responses.
Adoptive cell therapy: The infusion of autologous or engineered immune cells, for example T cells bearing tumour-specific receptors, to attack cancer cells.
References
- Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial. Signal Transduction and Targeted Therapy (2024).
- Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Journal of Experimental & Clinical Cancer Research (2022).
- Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers (2021).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.